ClinicalTrials.gov
public full text
Public Domain
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies
In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations#852694
- Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients#909683
- Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies#1377338
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)#912779
- An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients#1262667
Record · ID 1477781
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive